glp-1analogs
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| glp-1analogs [2026/05/19 22:02] – [Actions] wh | glp-1analogs [2026/06/09 09:48] (current) – [other human GLP-1RA analogs] gary1 | ||
|---|---|---|---|
| Line 94: | Line 94: | ||
| =====other human GLP-1RA analogs===== | =====other human GLP-1RA analogs===== | ||
| + | ====injectables==== | ||
| *teduglutide | *teduglutide | ||
| *dulaglutide | *dulaglutide | ||
| Line 99: | Line 100: | ||
| *albiglutide | *albiglutide | ||
| * approved in US in 2014, marketed as Tanzeum and Eperzan | * approved in US in 2014, marketed as Tanzeum and Eperzan | ||
| + | ====oral==== | ||
| + | *elecoglipron | ||
| + | * a Phase 2b trial published in 2026 seems to show good results although most reported GIT adverse effects such as nausea, constipation, | ||
| + | |||
| + | |||
| ===GIP and GLP-1 Receptor Agonists=== | ===GIP and GLP-1 Receptor Agonists=== | ||
| *tirzepatide (Mounjaro, Zepbound) | *tirzepatide (Mounjaro, Zepbound) | ||
glp-1analogs.txt · Last modified: 2026/06/09 09:48 by gary1